China National Pharmaceutical Group (Sinopharm) subsidiary obtained drug registration certificate for Metoprolol Hydrochloride Tablets.

China Finance APP reported that Guoyao Xiandai (600420.SH) announced recently that its wholly-owned subsidiary, Guoyao Group Rongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as Guoyao Rongsheng), received the Drug Registration Certificate for Metoprolol Hydrochloride Tablets issued by the National Medical Products Administration. Metoprolol Hydrochloride Tablets are used for the treatment of: 1. Primary hypertension; 2. Secondary hypertension caused by renal parenchymal lesions.